• 1
    Nadar S, Blann AD, Lip GY. Antihypertensive therapy and endothelial function. Curr Pharm Des 2004; 10: 360714.
  • 2
    Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des 2004; 10: 3591605.
  • 3
    Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel R, Lip GYH, Mancuso P, Sampol J, Solovey A, Dignat-George F. Circulating endothelial cells Biomarker of vascular disease. Thromb Haemostat 2005 ; 93: 22835.
  • 4
    Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis 2003; 14: 42531.
  • 5
    Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 52632.
  • 6
    Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 31415.
  • 7
    Páramo J, Beloqui O, Colina I, Diez J, Orbe J. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. J Thromb Haemost 2005; 3: 6624.
  • 8
    Blann AD, Waite MA. von Willebrand factor and soluble E-selectin in hypertension: Influence of treatment and value in predicting the progression of atherosclerosis. Coron Artery Dis 1996; 7: 1437.
  • 9
    Grewal J, Chan S, Frohlich J, Mancini GB. Assessment of novel risk factors in patients at low risk for cardiovascular events based on Framingham risk stratification. Clin Invest Med 2003; 26: 15865.
  • 10
    Lip GYH, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 25565.
  • 11
    Chong A-Y, Blann AD, Lip GYH. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. Q J Med 2003; 96: 25367.
  • 12
    Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26: 38691.
  • 13
    O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 1422.
  • 14
    Poulsen PL. ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria. J Renin Angiotensin Aldosterone Syst 2003; 4: 1726.
  • 15
    Mykkanen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins DC, Haffner SM. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28: 171016.
  • 16
    Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 1418.
  • 17
    Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood groups and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 60107.